stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Total debt
Insmed, Inc.'s total debt at the end of fiscal 2025 was $561.7M, down 50.2% from $1.1B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $562.8M. Over the past ten years it has ranged from $25.1M (fiscal 2015) to $1.2B (fiscal 2023); the current reading is higher than 64% of that period. Insmed, Inc. ranks 28th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $561.7M | (50.18%) |
| FY2024 | $1.1B | (4.64%) |
| FY2023 | $1.2B | 2.38% |
| FY2022 | $1.2B | 98.88% |
| FY2021 | $580.7M | 56.51% |
| FY2020 | $371.0M | 4.38% |
| FY2019 | $355.5M | 12.29% |
| FY2018 | $316.6M | 469.69% |
| FY2017 | $55.6M | 1.42% |
| FY2016 | $54.8M | 117.94% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $562.8M | 0.07% |
| Jun 2026 | $562.4M | 0.07% |
| Mar 2026 | $562.0M | 0.06% |
| Dec 2025 | $561.7M | 0.07% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| GMAB Genmab A/S Sponsored ADR compare | $5.1B |
| BBIO BridgeBio Pharma, Inc. compare | $1.9B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| INSM Insmed, Inc. | $562.8M |
| ASND Ascendis Pharma A/S compare | $523.3M |
| BNTX BioNTech SE Sponsored ADR compare | $414.1M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| EXEL Exelixis, Inc. compare | $191.0M |
| INCY Incyte Corporation compare | $27.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement